U.S. lawmakers push for more oversight of Elon Musk's Neuralink



By Rachael Levy

Dec 8 (Reuters) - U.S. House Representatives Earl Francis Blumenauer and Adam Schiff want further U.S. Department of Agriculture (USDA) scrutiny of Elon Musk's Neuralink following a Reuters report that outlined mistakes in the brain chip company's animal testing program, their offices said on Thursday.

Reuters reported on Monday that the USDA's inspector general is investigating Neuralink for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths.

Blumenauer and Schiff, two Democrats who are members of the Congressional Animal Protection Caucus, wrote in a draft letter they will send to the USDA that "the treatment of the animals described in these complaints seems to indicate a distressing lack of oversight."

"We are very concerned that this may be another example of high-profile cases of animal cruelty involving USDA-inspected facilities, referenced in previous letters to your agency, where there has not been adequate action from USDA," the lawmakers said in a letter addressed to USDA secretary Thomas Vilsack and Kevin Shea, who oversees the agency's inspection service.

Neuralink executives did not immediately respond to requests for comment. A USDA spokesperson said the agency could not comment on Neuralink and referred Reuters to the inspector general's office, which also declined to comment.

Reuters identified several problems with Neuralink's animal trials, including four experiments involving 86 pigs and two monkeys that were marred by human errors, following a review of dozens of previously unreported audio recordings, emails, messages, presentations, internal company reports and interviews with more than 20 current and former employees.

The mistakes weakened the experiments and required repeated tests, leading to more animals being killed. In total, the company has killed about 1,500 animals, including more than 280 sheep, pigs and monkeys, following experiments since 2018, Reuters found.

Blumenauer's and Schiff's offices declined to comment on what they want the USDA to do beyond the inspector general's investigation. The lawmakers wrote in their letter that the investigation was "vital to shedding light on the unnecessary animal suffering and deaths" and potential animal-welfare law violations.

The lawmakers also cite records made public by the Physicians Committee for Responsible Medicine, an animal advocacy group that released records related to Neuralink's partnership at the University California Davis, as grounds for concern. Neuralink has acknowledged that six monkeys died because of health problems in experiments it conducted with the university during their partnership that lasted from 2017 until 2020.

Schiff has also been critical of Musk's $44 billion acquisition of Twitter Inc, accusing him of "sabotaging safeguards against digital misinformation and hate."
Reporting by Rachael Levy in Washington, D.C.; Editing by Josie Kao

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.